OOIR: Observatory of International Research

Papers

(The TQCC of European Journal of Heart Failure is 2. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2022-08-01 to 2026-08-01.)

Article	Citations
Adrenomedullin as a Marker of Hypoxia, Not Hypoperfusion. Letter Regarding the Article ‘Biologically Active Adrenomedullin as a Marker for Residual Congestion and Early Rehospitalization in Patients H	420
Issue Information	240
Machine learning to reveal hidden HFpEF: promise, pitfalls, and next steps	190
	170
Issue Information	154
Tafamidis in Patients with Severe Heart Failure due to Transthyretin Amyloidosis Cardiomyopathy: Improved Long-Term Survival	151
Rationale and Design of the ESC Heart Failure III Registry – Implementation and Discovery	149
Effect of Dapagliflozin on Health Status and Quality of Life Across the Spectrum of Ejection Fraction: Participant-Level Pooled Analysis from the DAPA-HF and DELIVER Trials	124
Association Between Liver Fibrosis, Plasma Volume Status, and Cardiovascular Mortality: The Hiroshima Study on Glucose Metabolism and Cardiovascular Diseases	123
Clonal hematopoiesis is linked to increased risks of all-cause mortality, cardiovascular death, and bleeding complications in patients with atrial fibrillation	102
Effect of Sacubitril/Valsartan in Heart Failure with Preserved Ejection Fraction Across the Age Spectrum in PARAGON-HF	100
Time-Varying Analyses of Survival and Outcomes in Patients with HeartMate 3 Left Ventricular Assist Devices	97
Subclinical atrial fibrillation and the risk of heart failure: insights from ARTESiA	93
Letter regarding the article ‘Clinical profiles and prognostic impact of residual intravascular and tissue congestion in acute heart failure’	88
Striving for the ‘Perfect’ Definition of Iron Deficiency in Heart Failure	88
Identifying Reliable Biomarkers for Pulmonary Congestion: Toward a Close Yet Sustainable Heart Failure Follow-Up	86
Similarities and Distinctions Between Acetazolamide and Sodium–Glucose Cotransporter 2 Inhibitors in Patients with Acute Heart Failure: Key Insights Into ADVOR and EMPULSE	86
Reply to the letter regarding the article ‘Are mechanical circulatory supports the forgotten aspect in the implementation of therapies for heart failure?’	82
Applying the ‘Touch-and-Go’ Concept to Mineralocorticoid Receptor Antagonists: A Paradigm Shift in Routine Heart Failure Management	80
Dissecting the Heart Failure Phenotype Through Phenomics	78
Issue Information	78
Abstract	76
Letter Regarding the Article ‘Employment of Artificial Intelligence for an Unbiased Evaluation Regarding the Recovery of Right Ventricular Function After Mitral Valve Transcatheter Edge-To-Edge Repair	73
Reply to ‘Morphine use in acute cardiogenic pulmonary oedema: is MIMO trial enough to change practice?’	73
Expanding the Horizon of Medication Adherence Strategies in Acutely Decompensated Heart Failure. Letter Regarding the Article ‘Medication Adherence in Patients with Acutely Decompensated Heart Failure	73

Response to Letter EURJHF-25-1455	71
Are Left Ventricular Ejection Fraction Phenotypes Meaningful in Acute Heart Failure?	70
Cardiovascular Magnetic Resonance-Estimated Pulmonary Capillary Wedge Pressure, Congestion Markers, and Effect of Empagliflozin in Patients with Heart Failure with Reduced Ejection Fraction and Dysgly	69
Abstract	68
Characteristics and Outcomes of Patients with a History of Cancer Recruited to Heart Failure Trials	68
Correction to: Association of patient-centred remote monitoring with clinical outcomes in patients with prior hospitalization: the TELESAT PRIOR-HF study	67
Single-cell transcriptomics uncovers immune remodeling in heart failure complicated by myocarditis	67
Heterogeneity of ejection fraction recovery in acute heart failure with reduced ejection fraction: a phenotype-based analysis from a nationwide registry	66
Heterogeneity of recovery in HFrEF: biochemical and structural recovery phenotypes and prognosis	65
Impact of myocardial fibrotic changes assessed by magnetic resonance imaging on early postoperative outcomes after aortic valve replacement	64
Tirzepatide use in patients with heart failure with preserved ejection fraction and obesity in clinical practice	63
Early dapagliflozin therapy after STEMI in patients with preserved ejection fraction: a prospective cohort study	63
Prevalence and characterization of normotensive shock in intermediate-high risk acute pulmonary embolism patients	62
Factors associated with one-year maintenance of sinus rhythm after successful electrical cardioversion of persistent atrial arrhythmias in patients with cardiac implantable electronic devices	62
Invasive haemodynamics and advanced echocardiography to define the diagnostic and prognostic value of left atrial function in advanced heart failure	62
Early coronary angiography and survival in older adults with nstemi: a frailty-adjusted analysis	60
Role of balance and physical fitness in assessing the effectiveness of cardiac rehabilitation on functional recovery	60
Evolution of congestion during post-discharge follow-up in a heart failure unit	59
Hidden malnutrition and sarcopenic obesity in older heart failure outpatients	59
Reassessing treatment strategies for obstructive prosthetic valve thrombosis: fibrinolysis or urgent surgery?	58
Aortic valve stenosis is unrelated to the severity of transthyretin amyloid cardiomyopathy and is instead linked to aging	58
Genetic variants identify patients with myocarditis at higher risk for ICD implantation	57
Impact of sodium-glucose cotransporter-2 inhibitors on clinical outcomes in patients with valvular heart diseases and type 2 diabetes	57
Safety and efficacy of targeted pharmacotherapy in elderly patients with pulmonary arterial hypertension	56
A novel right ventricular morphofunctional index integrating geometry and RV pulmonary arterial coupling for risk stratification in heart failure	56
Validating prediction models for hypertrophic cardiomyopathy genotype positivity	55
Genotype-driven differences in the phenotype and prognosis of patients with hypertrophic cardiomyopathy	55
Heart failure with preserved ejection fraction in the elderly: clinical, imaging, and biomarker profiles according to global longitudinal strain by cardiac magnetic resonance	54
Admission NT-proBNP and in-hospital mortality in acute heart failure: a real-world emergency cohort study	54
Relationship between resting hemodynamic parameters and exercise capacity in patients with advanced heart failure: a single-centre experience	54
Enabling community management of patients with heart failure: the impact of a specialist nurse-facilitated shared-care model	53
Impaired global longitudinal strain predicted cardiovascular outcomes in incident peritoneal dialysis patients: a prospective study	53
Diastolic dysfunction precedes systolic failure in experimental right ventricular overload: a systematic review	53
Health literacy and heart failure-related knowledge in ambulatory patients with chronic heart failure: a cross-sectional study	53
Domains of senile asthenia syndrome in chronic heart failure: clinical and prognostic significance	52
Genotype and left ventricular reverse remodelling in familial dilated cardiomyopathy with contemporary heart failure therapy - the ReaGEN study	52
Mavacamten effectiveness and safety in the real-world setting and association with CYP2C19 metaboliser status: data from a canadian prospective registry	52
Impact of pre-existing heart failure on outcomes after pulmonary embolism: a prospective registry study	51
Mini-Cog as an independent determinant of medication self-management autonomy in hospitalized patients with heart failure	51
Specialist pharmacist-led rapid optimisation of patients with heart failure with reduced ejection fraction in the outpatient setting	50
Evaluation of lung and abdominal point-of-care ultrasound congestion findings at discharge to predict rehospitalization and death in adults with acute heart failure: systematic review and metaanalysis	50
Citokine networks and heart failure outcomes: CA125 as a bridge between congestion and inflammation	50
Predictors of mortality in the heart failure and chronic kidney disease co-morbid cohort	49
Renal phenotypes and 1-year mortality after acute decompensation in HFpEF: CKD vs AKI	49
Temporal trends in mineralocorticoid receptor antagonist use among patients with heart failure in a community-based cohort	49
The effect of ARNI and SGLT2i therapies on the inflammasome pathway in myocardial heart transplantation biobank samples	48
Vutrisiran-mediated knockdown of transthyretin in patients with transthyretin amyloidosis	48
Inflammatory and adipokine-associated proteomic signatures of heart failure progression by body mass index: insights from the EXAMINE trial	48
Effect of intravenous repletion of ferric hydroxide sucrose on the functional capacity of pacients with heart failure	48
Guideline-directed medical therapy use in adults with duchenne muscular dystrophy and heart failure with reduced ejection fraction	47

Diagnostic evaluation and recognition of HFpEF in routine clinical practice: a multicentre retrospective study	47
Predicting pacemaker implantation in ILR-monitored patients with suspected bradycardia: a head-to-head comparison of PREDICT-PPM, DROP, and EGSYS	47
Impacts of a rapid up-titration programme of guideline-directed medical therapy on quality of life: patient-reported outcomes from a multicentre heart failure study	47
Decongestion Strategies In Patients Presenting with Acutely Decompensated Heart Failure: A Worldwide Survey Among Physicians	46
Continuation versus discontinuation of beta-blockers during hospitalisation for viral pneumonia in patients with COPD and HFrEF	46
Exercise Catheterization in Adults Post-Fontan with Normal and Abnormal Haemodynamic Criteria: Insights Into Normal Fontan Physiology	46
Improved outcome up to 10 years after intravenous immunoglobulin therapy in patients with dilated cardiomyopathy	46
Sex differences in response to cardiac resynchronization therapy: the role of relative dyssynchrony - Does size matter in sex?	46
Clinical Profiles and Prognostic Impact of Residual Intravascular and Tissue Congestion in Acute Heart Failure	46
Heart failure in pregnancy: where the 2025 ESC Guidelines ‘cardiovascular disease and pregnancy’ illuminate—and where shadows remain	46
Weight loss and clinical decongestion across heart failure phenotypes: a post-hoc analysis of a multicentre randomised trial (duel-hf)	46
Culture, Ethnicity, and Socio-Economic Status as Determinants of the Management of Patients with Advanced Heart Failure who Need Palliative Care: A Clinical Consensus Statement from the Heart Failure	45
Percutaneous Repair of Moderate-to-Severe or Severe Functional Mitral Regurgitation in Patients with Symptomatic Heart Failure: Baseline Characteristics of Patients in the RESHAPE-HF2 Trial and Compar	45
Early SGLT2 inhibition in acute heart failure: when more urine does not necessarily mean better decongestion	45
Burst Steroid Therapy for Acute Heart Failure: The CORTAHF Randomized, Open-Label, Pilot Trial	45
Left ventricular volume and maximal functional capacity in heart failure with preserved ejection fraction: Size matters	45
Salt Repletion and Diuretic Response: The Role of Serum Chloride. A Post-hoc Analysis of the SALT-HF Trial on Furosemide and Hypertonic Saline Solution Administration in Ambulatory Patients with Worse	44
Finerenone, Chronic Obstructive Pulmonary Disease, and Heart Failure with Mildly Reduced or Preserved Ejection Fraction: A Prespecified Analysis of the FINEARTS-HF Trial	44
Incidence and Predictors of Weaning Failure From Veno-Arterial Extracorporeal Membrane Oxygenation Therapy in Patients With Cardiogenic Shock	44
Atrial Cardiomyopathy: From Healthy Atria to Atrial Failure. A Clinical Consensus Statement of the Heart Failure Association of the ESC	44
Exercise cardiac magnetic resonance biventricular volumetric reserve in heart failure with preserved ejection fraction	44
Corrigendum to ‘Congestion in Heart Failure: A Circulating Biomarker-Based Perspective’ and Articles Listed Below	44
Vericiguat Global Study in Participants with Chronic Heart Failure: Design of the VICTOR Trial	44
Determinants of Submaximal Exercise Intolerance in Patients with Heart Failure and Preserved Ejection Fraction: Insights from the Lactate Threshold	44
Sacubitril/Valsartan Versus Enalapril in Chronic Chagas Cardiomyopathy with Heart Failure: Baseline Characteristics of the PARACHUTE-HF Trial	43
Effect of the cardiac myosin activator omecamtiv mecarbil on ventricular arrhythmias, cardiac arrest, and sudden death in heart failure with reduced ejection fraction: the GALACTIC-HF trial	43
404-Error “Disease Not Found”: Unleashing the Translational Potential of -Omics Approaches Beyond Traditional Disease Classification in Heart Failure Research	43
Impact of multicomponent exercise training in older individuals with and without heart failure with reduced ejection fraction: the role of functional capacity and novel biomarkers	43
A novel cardio-vascular media enable to assess the complexity of multicellular organoids	42
The Different Risk of New-Onset, Chronic, Worsening, and Advanced Heart Failure: A Systematic Review and Meta-Regression Analysis	42
Remote Patient Management of Heart Failure Across the Ejection Fraction Spectrum: A Pre-Specified Analysis of the TIM-HF2 Trial	42
Sex Differences in the Generalizability of Randomized Clinical Trials in Heart Failure with Reduced Ejection Fraction	42
Aortic Valve Disease and Heart Failure with Mildly Reduced Ejection Fraction: New Insights and Pending Questions	41
July 2023 at a Glance: Heart Failure with Preserved Ejection Fraction and Comorbidities	41
Low Blood Pressure and the Effect of Empagliflozin in Acute Heart Failure: An EMPULSE Analysis	41
Issue Information	40
Cardiopulmonary functional capacity: another piece of the puzzle of sodium–glucose cotransporter 2 inhibition in heart failure?	39
The dangerous liaison between epicardial adipose tissue and heart failure with preserved ejection fraction	39
	39
Issue Information	39
Correction to “Use of Guideline-Recommended Medical Therapy in Patients with Heart Failure and Chronic Kidney Disease: from Physician's Prescriptions to Patient's Dispensations, Medication Adherence a	38
Reply to ‘A clinical classification method with outstanding advantages for quickly identifying hazardous types’	38
Integrated Trajectories of Systolic and Diastolic Function Differentially Associate with Risk for Heart Failure with Preserved and Reduced Ejection Fraction and Proteomic Profiles	38
Predicting worsening heart failure with preserved ejection fraction from non‐invasive exercise testing	38
Letter Regarding the Article ‘Association Between Antecedent Myocardial Infarction and Heart Failure with Preserved Versus Reduced Ejection Fraction’	38
Letter Regarding the Article ‘Efficacy and Safety of Angiotensin Receptor–Neprilysin Inhibition in Heart Failure Patients with End-Stage Kidney Disease on Maintenance Dialysis: A Systematic Review and	37
The Cost-Effectiveness of Dapagliflozin in Heart Failure with Preserved or Mildly Reduced Ejection Fraction: A European Health-Economic Analysis of the DELIVER Trial	37
Iron deficiency definitions and their clinical and prognostic associations across the spectrum of left ventricular ejection fraction in heart failure	37
Weight Change and Clinical Outcomes in Heart Failure with Reduced Ejection Fraction: Insights from EMPEROR-Reduced	37
Iron deficiency in HFpEF: a true clinical divergence or a competing risk artefact?	37
Transcriptomic analysis reveals immune and metabolic signatures correlated with prognosis in DCM and NDLVC	36
Patient perceived physician empathy, treatment adherence and quality of life predict mid-term outcomes in heart failure	36
Prognostic impact of left atrial strain, GLS LV and atrial mitral regurgitation in patients with HFpEF and atrial fibrillation	36
Admission congestion phenotypes and 6-month outcomes after heart failure hospitalisation	36
Favorable effects of sacubitril/valsartan treatment on cardiac autonomic function parameters in patients with heart failure and reduced ejection fraction	35
U-shaped relationship between LDL cholesterol and clinical outcomes in lipid-lowering therapy-naive patients with nonischemic heart failure with reduced ejection fraction	35
Can we prevent sudden cardiac death?	35
Underserved communities at risk of heart failure: effectiveness of community-based recruitment strategies and burden of unrecognised cardiovascular disease	34
Titin truncating variants impair myocardial thick-filament activation during stretch and blunt length-dependent activation mediating Frank-Starling	34
Patient radiation exposure during invasive graft surveillance after heart transplantation	34
Mortality predictors and prognostic implications of intermittent levosimendan therapy in advanced heart failure	34
Glucose-independent effects of empagliflozin on gap junction and extracellular matrix remodeling in volume overload heart failure	34
Persistent and progressive dysfunction of mitochondria following brief episodes of hypoxia in dogs with chronic heart failure	34
Regional heterogeneity in adult vaccination uptake among remotely monitored heart failure patients in France: a cross-sectional survey	34
The influence of QRS duration and resynchronization status on the efficacy and safety of omecamtiv mecarbil in heart failure with reduced ejection fraction: the GALACTIC-HF trial	34
Physiologic correlates of in-hospital weight loss in acute heart failure: insights from bioimpedance analysis	33
Mechanical complications after acute myocardial infarction: a 15-year single-center experience	33
Serum transthyretin decline: an early warning signal for heart failure in hATTR-CM	33
Major bleeding and mortality in cardiogenic shock: insights from the SMART-RESCUE II shock registry	33
Stage 2 cardiovascular-kidney-metabolic syndrome and the risk of heart failure	33
Transcatheter versus surgical aortic valve replacement in bicuspid aortic stenosis: baseline characteristics and early clinical outcomes	33
Clinical outcomes of beta-blocker therapy after myocardial infarction in patients with preserved or mildly reduced ejection fraction	33
The influence of cardiovascular risk-related comorbidities on the development of dilated cardiomyopathy	32
End-diastolic aortic gap on initial cardiac ct and prognosis in lvad patients: comparison with echocardiographic aortic regurgitation	32
Non-invasive assessment of pulmonary capillary wedge pressure using a dual-modal wearable system and physics-informed artificial intelligence: a validation study against right heart catheterization	32
Association of SGLT2 inhibitors and new-onset dementia in non-diabetic patients with heart failure	32
Oxygen uptake recovery and impaired cardiac reserve capacity: interaction with tau parameter	32
Role of vericiguat on renal function decline in patients with worsening heart failure	32
The main possible risk factors occurrence of atrial fibrillation in patients with heart failure preserved ejection fraction	31
Impact of SGLT2 inhibitors on functional class in patients with transthyretin cardiac amyloidosis: a retrospective matched study	31

Right ventricular-pulmonary artery coupling as a tool for clinical prioritization in severe aortic stenosis	31
Exercise-induced oxygen desaturation identifies early post-discharge risk in patients with heart failure	31
Burden of wild-type transthyretin amyloid cardiomyopathy hospitalizations	31
Left atrial volume index predicts clinical outcomes in patients with acute heart failure	31
Idiopathic premature ventricular contractions: a retrospective longitudinal analysis of the association with ventricular dysfunction and cardiovascular outcomes	31
Circulating biomarkers and proteomic profile changes in elderly patients with heart failure with improved ejection fraction: a real-life study	31
Recovery of worsening renal function after acute heart failure	31
Efficacy and Safety of Finerenone in Patients with Chronic Kidney Disease and Type 2 Diabetes By Diuretic Use: A FIDELITY Analysis	30
Sustained low-efficiency dialysis for refractory congestion in advanced cardiorenal syndrome: haemodyamics and weight reduction analysis	30
Normal and Excessive Muscle Sympathetic Nerve Activity in Heart Failure: Implications for Future Trials of Therapeutic Autonomic Modulation	30
Finerenone According to Insulin Resistance in Heart Failure: Insights from the FINEARTS-HF Trial	30
Effect of Long-Term Tafamidis Treatment on Health-Related Quality of Life in Patients with Transthyretin Amyloid Cardiomyopathy	29
Diagnostic Pathways to Wild-Type Transthyretin Amyloid Cardiomyopathy: A Multicentre Network Study	29
Predicting Survival in Patients with Severe Heart Failure: Risk Score Validation in the HELP-HF Cohort	29
Indexing left ventricular end‐systolic dimension to body size: Association with mortality in patients with degenerative mitral regurgitation	29
Heart Failure Improvement, Remission, and Recovery: A European Journal of Heart Failure Expert Consensus Document	29
Use of Mechanical Circulatory Support in Patients with Non-Ischaemic Cardiogenic Shock	28
Serial Direct Sodium Removal in Patients with Heart Failure and Diuretic Resistance	28
Erythropoietic Response After Intravenous Iron in Patients with Heart Failure and Reduced Ejection Fraction with and Without Background Treatment with Sodium–Glucose Cotransporter 2 Inhibitors	28
Digitalis – back on centre stage for HFrEF	28
Health Status Across Major Subgroups of Patients with Heart Failure and Preserved Ejection Fraction	28
Landscape of Glycolytic Metabolites and Their Regulating Proteins in Myocardium from Human Heart Failure with Preserved Ejection Fraction	28
Changes in Mid-Regional Pro-Adrenomedullin During Treatment with Sacubitril/Valsartan	27
European Society of Cardiology updated curriculum for heart failure nurses: developed by the Heart Failure Association, in collaboration with the Association of Cardiovascular Nurses and Allied Profes	27
Application of a Transthyretin Amyloid Cardiomyopathy Score to Heart Failure with Mildly Reduced or Preserved Ejection Fraction	27
Kidney Injury in Patients with Heart Failure-Related Cardiogenic Shock: Results from an International, Multicentre Cohort Study	27
Hemodynamic changes in response to GLP-1 treatment in ICD and CRT patients: insights from HeartLogic sensor data	27
Diuretics in Pregnancy: Data from the ESC Registry of Pregnancy and Cardiac Disease (ROPAC)	27
Low-Dose Digoxin Improves Cardiac Function in Patients with Heart Failure, Preserved Ejection Fraction and Atrial Fibrillation – the RATE-AF Randomized Trial	27
Late Diagnosis in Cancer Sparks Outrage—So Why Not Heart Failure?	27
Reply to ‘Is Sodium Chloride Supplementation Ready for Clinical Practice in Acute Heart Failure?’	26
What's New in Heart Failure? October 2025	26
CDK4/6 inhibitor ribociclib induces cardiotoxicity through impaired E2F1-regulated spliceosome assembly	26
Enrolling patients in cardiogenic shock trials: are we missing someone? Insights from the Italian AltShock‐2 registry	26
Decreased Left Ventricular Ejection Fraction is Associated with Increased Mortality in Sepsis: A Retrospective Cohort Study	26
Comparison of Pulmonary Congestion Severity Using Artificial Intelligence-Assisted Scoring Versus Clinical Experts: A Secondary Analysis of BLUSHED-AHF	26
Managing Water and Salt Balance in Heart Failure: Is There Anything Else to Consider Other than Diet and Diuretics?	26
Comparative Effectiveness of Sacubitril/Valsartan Versus Angiotensin-Converting Enzyme Inhibitors/Angiotensin Receptor Blockers in Patients with De Novo Heart Failure with Mildly Reduced and Preserved	26
More than Just a Clinical Syndrome: Biomarkers and Echocardiography Should be Rapidly Advised for Anyone with Suspected Heart Failure!	26
Corrigendum to “Sex Differences in Proteomic Correlates of Coronary Microvascular Dysfunction Among Patients with Heart Failure and Preserved Ejection Fraction”	26
BET proteins link epigenetic remodeling to impaired autophagy in HFpEF	26
Letter regarding the article ‘evaluating early cardiology involvement and survival outcomes across NT-proBNP levels: an island-wide retrospective cohort study’	26
Biventricular Cardiac Power Reserve in Heart Failure with Preserved Ejection Fraction	26
No Longer from Pillar to Post: The First Effective Step in Treating Heart Failure with Preserved Ejection Fraction	26
Predicting Heart Failure: The Promise of Proteomics	26
Reply to the Letter Regarding the Article ‘Head-to-Head Comparison Between Recommendations by the ESC and ACC/AHA/HFSA Heart Failure Guidelines’	25
Artificial Intelligence in Heart Failure Improving the Efficiency or Dependency on it? Letter Regarding the Article ‘Artificial Intelligence and Heart Failure: A State-of-the-Art Review’	25
	25
Analysing the Accuracy of Pressure Measurements During Exercise with Pulmonary Artery Pressure Sensors – Insights from the ACTION-MEMS Study	25
Heart Failure After Left Atrial Appendage Occlusion: Insights from the LAAOS III Randomized Trial	25
Delivering more evidence for the specificities of heart failure with improved ejection fraction: New answers, new questions	25
Revolutionizing Cardiogenic Shock Treatment: Is the Microaxial Flow Pump the Ultimate Game Changer?	25
	25
Long‐term survival after acute heart failure hospitalization: from observation to collaborative interventions	24
An Individual Treatment Effect Approach to Predict Response to Mineralocorticoid Receptor Antagonists in Patients with Heart Failure and Reduced Ejection Fraction	24
Letter Regarding the Article ‘Guideline-Directed Medical Therapy for Heart Failure in Arrhythmia-Induced Cardiomyopathy with Improved Left Ventricular Ejection Fraction’	24
Differential Sex-Related Effect of Left Ventricular Ejection Fraction Trajectory on the Risk of Mortality and Heart Failure Readmission Following Hospitalization for Acute Heart Failure: A Longitudina	24
Reporting Quality of Heart Failure Randomized Controlled Trials 2000–2020: Temporal Trends in Adherence to CONSORT Criteria	24
Heart rate modulation in heart failure with preserved ejection fraction: lessons from nature	24
Reply to ‘Sodium–glucose cotransporter 2 inhibitor treatment lowers serum uric acid in patients with heart failure with reduced ejection fraction – lessons from clinical trials’	24
Trajectories in New York Heart Association functional class in heart failure across the ejection fraction spectrum: data from the	24
Surrogate markers of clinical endpoints in clinical trials of heart failure	24
Acute Heart Failure Care – a Consensus Series of an International Experts' Group	24
Impact of COVID-19 in Patients with Heart Failure with Mildly Reduced or Preserved Ejection Fraction Enrolled in the DELIVER Trial	23
Phenotypic clusters and sacubitril/valsartan in heart failure with preserved ejection fraction: a PARAGON-HF substudy	23
Predictors of cardiac involvement in myotonic dystrophy type 1: a retrospective study	23
Exercise cardiac magnetic resonance imaging in heart failure with preserved ejection fraction: impact of central obesity on exercise capacity - the EXPOSURE study	23
Remote monitoring and mortality outcomes in heart failure patients with cardiac implantable devices in an ultra-peripheral region	23
SGLT2 inhibition prevents apex-specific cardiac dysfunction and inflammation in an experimental model of Takotsubo Syndrome	23
Video Thermography Uncovers Relationship Between Volume Status and Temperature in Heart Failure	23
Predictors of metabolic heart failure with preserved ejection fraction in patients with nonalcoholic fatty liver disease	23
Differences between men and women in guideline-directed medical therapy implementation, tolerability, and outcomes in HFrEF.	23
Left ventricular transmural pressure and ventilatory inefficiency during exercise in advanced heart failure	23
Prognostic impact of gamma-glutamyltransferase in transthyretin amyloid cardiomyopathy	23
How ultra-rare is danon disease? an estimate of prevalence based on multiple data sources	23
Pilot study on hemodynamic monitoring in patients with advanced heart failure - comparison of non-invasive versus invasive hemodynamic monitoring	23
Insights into accessory pathway ablation: a descriptive study from a tertiary care center	23
Anti-arrhythmic drug use signals higher recurrence risk of accessory pathways after ablation	23
Admission hypochloremia predicts prolonged hospital stay and adverse in-hospital outcomes in congestive heart failure: A quantile regression analysis of 3,454 patients	23
Improvement of size, shape but not RV function with sotatercept in pulmonary arterial hypertension: insights from a french nationwide real-world echocardiographic study	22
Incremental prognostic value of clinical, functional and imaging variables in acute myocarditis: a hierarchical risk modelling approach	22
Role of carbohydrate antigen 125 in predicting right ventricular dysfunction and right ventricular to pulmonary artery uncoupling in acute heart failure	22
Differential effect of antiobstructive therapy on mitral valve morphology in hypertrophic obstructive cardiomyopathy: a comparison of myosin inhibition and PTSMA therapy	22
In-hospital mortality in acute ST-elevation myocardial infarction: prevalence and associated predictors	22
Identifying clinical determinants of TAVI futility in a real-world cohort	22
Real-world treatment patterns and preferences in patients with transthyretin amyloid cardiomyopathy from Germany and Spain	22
Radiofrequency sensing enables non-invasive cardiac hemodynamic monitoring	22
High-risk acute heart failure patients in ward. should they be admitted in intensive care unit? report from a second level hospital	22
Risk-score performance for detecting transthyretin cardiac amyloidosis in severe aortic stenosis: a prospective cohort study	22
Impact of optimized medical therapy and telemonitoring on functional status and rehospitalization in patients with chronic heart failure: a prospective cohort study	21
Long-term clinical outcomes of vasodilating beta-blockers in acute myocardial infarction patients with preserved left ventricular ejection fraction after a successful stent implantation	21
Cardiorenal interaction in type 2 diabetes: asymptomatic or symptomatic adverse cardiac remodeling associates with declining renal function	21
A comparison of thigh skeletal muscle volume in heart failure phenotypes assessed by an advanced magnetic resonance imaging sequence	21
Efficacy and safety of sacubitril-valsartan versus enalapril in patients with heart failure due to Chagas cardiomyopathy: a systematic review and meta-analysis	21
Impact of guideline-directed medical therapies on clinical and economic outcomes in nonobstructive hypertrophic cardiomyopathy: analysis of data from a multinational cross-sectional survey	21